YIDU TECH (02158) has repurchased 17 times within one month. The clinical evidence-based intelligent system "Yidu Zhixun" has started internal testing.

On February 24, YIDU TECH (02158) announced its latest share repurchase plan: the company repurchased 720,000 shares at a price of approximately HK$5.96 per share, totaling nearly HK$4.3 million, continuing its intensive repurchase pace since 2026. Since January 26, the company has completed 17 repurchases, totaling over HK$72 million, demonstrating its dual confidence in its own development and industry prospects through continuous capital actions. According to reliable sources, YIDU TECH's clinical evidence-based intelligent system "Yidu Zhixun" has started internal testing. It is understood that this product is designed for clinical physicians and medical researchers, focusing on the real needs of clinical diagnosis and treatment as well as research scenarios. This round of internal testing invites frontline doctors with real practice backgrounds to participate, further optimizing the product's clinical practicality based on feedback from real practice scenarios. Previously, its creation "Doctor Copilot" was called nearly a thousand times a day in a single hospital, covering about 70% of clinical medical personnel and becoming a reliable partner throughout the entire process of doctor diagnosis and treatment. The launch of "Yidu Zhixun further enriches its intelligent system product matrix. Currently, the AI medical industry is being driven by both policy and technology. The "Implementation Opinions on the Development of 'Artificial Intelligence + Medical Health' Applications" jointly issued by eight ministries and commissions clearly states the goal of achieving full coverage of intelligent assisted diagnosis in secondary and above hospitals by 2030, making clinical evidence-based tools a crucial need for the industry. YIDU TECH is continuously repurchasing shares to convey value recognition, accelerating product innovation, and strengthening its competitiveness in the AI medical field, making its long-term development worth looking forward to.